VolitionRx Announces Pricing of $4.6 Million Public Offering

Impact · against what's priced in

VolitionRx is facing immediate equity dilution through a $4.6 million public offering. While the capital provides a necessary runway for its clinical-stage operations, the issuance of nearly 3 million shares and accompanying warrants creates a downward pressure on the share price.

VNRX−0.20

No priced-in read yet

In context

The company is pricing a public offering of 2,960,000 shares and warrants at $1.55 per share, which will dilute existing shareholders despite raising $4.6 million in gross proceeds.

Read from the article alone

• biotech▲12%
• healthcare
• VNRX
• capital markets
• epigenetics
• equity raise
• public offering
• warrants

Top 1 mover · tap to explore